Table 1

Clinical manifestations of vasculitis and COVID-19 in two patients with eosinophilic granulomatosis with polyangiitis (EGPA)

Duration EGPAManifestations EGPATreatment EGPASymptoms COVID-19Outcome
33/M1 yearNasal polyposis, sinusitis, asthma, pulmonary infiltrates, rashes, lacrimal gland involvement, MPO-ANCA positivePrednisone 7 mg, mepolizumab 300 mg SQ Q4 weeks, omalizumab 150 mg SQ Q4 weeksFatigue, myalgias, headache, sore throat, fevers, chills, cough, diarrhoea, anosmia, lack of tasteResolution after 14 days, no flare asthma or EGPA
52/M3 yearsNasal polyposis, sinusitis, asthma, bronchiectasis, rashes, splinter haemorrhages, ANCA negativePrednisone 2.5 mg alternating with 5 mg every other day, mepolizumab 300 mg SQ every 4 weeksFatigue, myalgias, fever, headache, nasal congestion, cough, decreased sense of smellResolution after 10 days, no flare asthma or EGPA
  • .ANCA, antineutrophil cytoplasmic antibody; M, male; MPO, myeloperoxidase; SQ, subcutaneous.